erlotinib hydrochloride has been researched along with mp470 in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (mp470) | Trials (mp470) | Recent Studies (post-2010) (mp470) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 30 | 3 | 26 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | mp470 (IC50) |
|---|---|---|---|
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | 1.6 | |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 2.55 | |
| Tyrosine-protein kinase receptor UFO | Homo sapiens (human) | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bearss, D; Cooke, LS; Croce, KD; Mahadevan, D; Qi, W; Riley, C; Saldanha, JW; Stejskal, A | 1 |
| Cooke, LS; Kurtzman, D; Mahadevan, D; Morales, C; Ong, E; Qi, W; Stejskal, AE; Swart, R; Theiss, N; Zhu, M | 1 |
2 other study(ies) available for erlotinib hydrochloride and mp470
| Article | Year |
|---|---|
MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumor growth in prostate cancer.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Drug Therapy, Combination; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Mice; Mice, SCID; Multigene Family; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Prostatic Neoplasms; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Thiourea | 2009 |
Novel receptor tyrosine kinase targeted combination therapies for imatinib-resistant gastrointestinal stromal tumors (GIST).
Topics: Afatinib; Aged; Aged, 80 and over; Axl Receptor Tyrosine Kinase; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Female; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Immunoblotting; Immunohistochemistry; Male; Middle Aged; Molecular Targeted Therapy; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins c-met; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Thiourea | 2015 |